Thanks @Wilba32
It definitely will be interesting to see the full results from these two trials for Remestemcel-L, especially if the control group crossover and receive Remestemcel-L treatment after 3 months and show similar positive findings
Takeda may be interested in Remestemcel-L now too given what they use Alofisel® for - to treat complex perianal fistulas in Crohn's disease ?
All early days yet and more studies are required, however it doesn't mean someone won't reach out to partner this indication for Chron's Disease and/or UC .... let's see how good the full results are when they are presented..... GLTAH
https://www.clinicaltrials.gov/ct2/show/NCT04548583?term=Remestemcel-L&draw=2&rank=18
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis
https://www.clinicaltrials.gov/ct2/show/NCT04543994?term=Remestemcel-L&draw=2&rank=13
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC) (UC)
Crohn’s Disease, page-45
-
- There are more pages in this discussion • 106 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |